Global Bispecific Antibody Market Reaches $13 Billion in First Three Quarters of 2025, Projected to Exceed $17 Billion for Full Year

▎Armstrong

In the first three quarters of 2025, the global bispecific antibody new drug market size reached 13 billion USD (Akeso's two bispecific antibodies have not yet disclosed sales data), a year-on-year increase of 33%, and it is expected to exceed 17 billion USD for the whole year.

Roche's anti-coagulant FIX/FX bispecific antibody Hemlibra achieved sales of $4.672 billion in the first three quarters, with an estimated annual revenue exceeding $6 billion.

Roche's VEGF/Ang2 bispecific antibody is the best-selling new anti-angiogenic drug in ophthalmology, with sales of $3.921 billion in the first three quarters, expected to exceed $5 billion for the full year.

Amgen's CD3/CD19 bispecific antibody Blincyto achieved sales of $1.146 billion in the first three quarters, with an estimated annual sales exceeding $1.5 billion. It is currently actively exploring autoimmune indications. The CD3/DLL3 bispecific antibody for solid tumors reached sales of $393 million in the first three quarters, in a rapid scaling phase, with an estimated annual sales surpassing $600 million.

Johnson & Johnson's EGFR/cMET bispecific antibody is in the rapid growth phase, with an estimated annual revenue of over $700 million. The combined annual sales of two blood cancer bispecific antibodies are expected to exceed $1 billion.

Akeso is the global leader in bispecific antibodies, with PD-1/CTLA-4 and PD-1/VEGF being the world's first immunological bispecific antibodies. Specific sales figures have not been disclosed yet, but both are in the rapid growth phase.

Summary

The bispecific antibody drug market size is expected to continue its rapid expansion in the coming years. TCE itself is also tapping into the autoimmune market, which represents another new track with extremely high potential. Akeso's tumor immunotherapy bispecific antibodies, including PD-1/VEGF, are expected to iterate on PD-1 and become a new cornerstone of immunotherapy, prompting many multinational corporations (MNCs) to invest in this direction. In summary, the bispecific antibody drug market is at the turning point before a second phase of high-speed growth, and there will be numerous breakout points emerging in the next few years.